Literature DB >> 21044275

Interpretation of RNFLT values in multiple sclerosis-associated acute optic neuritis using high-resolution SD-OCT device.

Nermin Serbecic1, Sven C Beutelspacher, Karl Kircher, Andreas Reitner, Ursula Schmidt-Erfurth.   

Abstract

PURPOSE: Optical coherence tomography (OCT) has emerged as the technique of choice in measuring the retinal nerve fibre layer (RNFL) quantitatively. It is suggested that RNFL reduction may correlate with lesion burden and diffuse axonal degeneration in the whole CNS of patients with multiple sclerosis (MS). However, RNFL changes because of optic neuritis (ON) must be taken into account.
METHODS: Twenty-three patients with acute ON (46 eyes) associated with clinical definite MS (23 ON eyes, 23 fellow eyes) and 23 sex- and age-matched healthy controls were studied. Retinal nerve fibre layer thickness (RNFLT) was measured at baseline, using a high-resolution spectral domain OCT (SD-OCT) applying circular, peripapillary OCT scans with a novel eye-tracking mechanism.
RESULTS: The internal OCT software was able to identify RNFL atrophy in three out of five of the acute ON eyes and one out of four of the fellow eyes with previous ON episodes. Retinal nerve fibre layer thickness of two ON (8.7%) and five fellow eyes (21.7%) was overestimated, thus located within the 95% and 5% confidence interval of the company standard values (not marked pathologic). In contrast, our comparison with age- and sex-matched controls revealed RNFL atrophy suggestive of prior, clinically silent RNFL loss in ON and fellow eyes (30.4%).
CONCLUSION: Retinal nerve fibre layer thickness measurements at a single time-point seem to have a limited role in detecting prior clinically silent optic nerve injury. Our data suggest that affected eyes should be compared with the fellow eyes and a sufficient number of age- and sex-matched controls to allow the detection of even subtle RNFL changes at baseline. The role of OCT for disease monitoring of MS must be evaluated in detail, as ON is often the initial symptom of MS.
© 2010 The Authors. Acta Ophthalmologica © 2010 Acta Ophthalmologica Scandinavica Foundation.

Entities:  

Mesh:

Year:  2010        PMID: 21044275     DOI: 10.1111/j.1755-3768.2010.02013.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  5 in total

1.  High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years.

Authors:  Nermin Serbecic; Fahmy Aboul-Enein; Sven C Beutelspacher; Clemens Vass; Wolfgang Kristoferitsch; Hans Lassmann; Andreas Reitner; Ursula Schmidt-Erfurth
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

2.  Detection of Retinal Nerve Fiber Layer Defects in Alzheimer's Disease Using SD-OCT.

Authors:  Robert Kromer; Nermin Serbecic; Lucrezia Hausner; Lutz Froelich; Fahmy Aboul-Enein; Sven C Beutelspacher
Journal:  Front Psychiatry       Date:  2014-02-25       Impact factor: 4.157

3.  Investigation of Altered Spontaneous Brain Activities in Patients With Moyamoya Disease Using Percent Amplitude of Fluctuation Method: A Resting-State Functional MRI Study.

Authors:  Chu-Qi Li; Qian-Min Ge; Hui-Ye Shu; Xu-Lin Liao; Yi-Cong Pan; Jie-Li Wu; Ting Su; Li-Juan Zhang; Rong-Bin Liang; Yi Shao; Er-Ming Zeng
Journal:  Front Neurol       Date:  2021-12-24       Impact factor: 4.003

4.  Comparison of visual evoked potentials and retinal nerve fiber layer thickness in Alzheimer's disease.

Authors:  Robert Kromer; Nermin Serbecic; Lucrezia Hausner; Lutz Froelich; Sven C Beutelspacher
Journal:  Front Neurol       Date:  2013-12-16       Impact factor: 4.003

5.  CROP - The Clinico-Radiologico-Ophthalmological Paradox in Multiple Sclerosis: Are Patterns of Retinal and MRI Changes Heterogeneous and Thus Not Predictable?

Authors:  Fahmy Aboulenein-Djamshidian; Martin Krššák; Nermin Serbecic; Helmut Rauschka; Sven Beutelspacher; Ivica Just Kukurová; Ladislav Valkovič; Adnan Khan; Daniela Prayer; Wolfgang Kristoferitsch
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.